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At the time of writing (2 December 2020) there were 51 candidate 
vaccines for COVID-19 in clinical evaluation.[1] The proviso ‘at the 
time of writing’ is particularly pertinent in a world where COVID-19 
vaccine development has been quite astonishingly rapid. Vaccines 
generally take up to 10 years to get to market, with five stages of 
development:[2] discovery-research, taking 2 - 5 years; preclinical, 
taking 2 years; clinical development (with three phases, phase I, 
taking 1 - 2 years; phase II, taking 2 - 3 years; and phase III, taking 
2 - 4 years); regulatory review and approval, taking 1 - 2 years; and 
finally manufacturing and delivery. Clinical development answers 
three questions: is it safe? does it activate an immune response? 
and does it protect against the disease? Manufacturing vaccines 
requires specialist facilities that are highly regulated and expensive to 
develop, usually starting following phase II clinical trials to develop 
the thousands of doses required for phase III trials. COVID-19 
vaccines went into human testing in March this year,[2] and the UK 
approved the Pfizer/BioNTech COVID vaccine for rollout – yes, 
actually injecting the vaccine into people – on 2 December. Vaccine 
programmes will start from the week beginning 7 December in the 
UK, targeting a highly selected group of vulnerable people.[3] This is 
an astonishing 9 months since the first trials started.
At the time of writing there are three vaccines, including the Pfizer/
BioNTech one, that are just about ready for rollout (I am not inclu ding 
the Russian or Chinese vaccines that are being rolled out, because we 
have no reliable data on their efficacy and safety – as someone said 
to me regarding the Russian vaccine when it was announced, ‘Stick 
to the sausages’). Two, including the Pfizer/BioNTech vaccine, are 
mRNA vaccines. The second of these, the Moderna mRNA-1273, was 
filed for Emergency Use Authorization with the US Food and Drug 
Administration on 30 November 2020 on completion of their phase 
III trial. These two vaccines have reported efficacy in the region of 
95%. The third is a vaccine being co-investigated by AstraZeneca and 
Oxford University (Oxford/AstraZeneca), with trials taking place in 
South Africa, which reports 70% efficacy, with a possible increase 
up to 90% depending on the dosing schedule. However, questions 
are being asked about whether these results stand up to scrutiny. [4] 
At the moment this is equivocal, with methodological issues that 
include pooling phase III trial data from two separate trials, one in 
the UK, the other in Brazil, along with a ‘glaring mistake’ in the way 
one of the two trials was conducted, in which some UK participants 
got roughly half of the intended dose of their first shot. Although this 
led to the happy finding of greater efficacy (maybe!) with this dosing 
schedule, the dosing error violated the trials protocol, which means 
that there are reasons to doubt the overall numbers. Simply put, too 
small a number of people received the half dose rather than the full 
dose, leading to an underpowered trial because of inadequate sample 
size. As well as that potential problem, the two separate phase III 
trials were performed under different protocols; the UK conducted a 
combined phase II/III trial, while that in Brazil was a pure phase III 
trial. Both used different placebos. All this potentially leads to some 
pretty complex statistical number crunching to take these differences 
into account, and as yet, details of the methodology haven’t been 
published. The results of the UK trial have been published in The 
Lancet,[5] but the full combined results are still to be submitted to a 
journal. Another possible confounding factor is that the people in 
the half-dose group were younger on average than participants as 
a whole, and vaccines usually work better in younger people. And 
COVID-19 is particularly severe in those over the age of 60 years. So, 
it looks as though the efficacy of this vaccine is probably somewhere 
between 62% and 90%  – full results still to be announced – which on 
balance is probably pretty good, and hopefully all the methodological 
issues will be ironed out as the trials continue.
And now to the nitty-gritty. Will we get a vaccine, any vaccine, 
here in South Africa and across the rest of the continent any time 
soon? The first two vaccines, which are likely to be the first to be 
available in any numbers, need to be stored at –70°C, but can then 
last for a few days in a normal fridge for transportation. Both require 
two doses, 28  days apart. The Oxford/AstraZeneca vaccine is not 
an mRNA vaccine and so can be stored in a normal fridge, making 
cold-chain issues far less of a problem, and also requires two doses. 
We know that with the best will in the world, cold chains are broken 
and the logistics around storing and distributing the mRNA vaccines 
probably make them pretty much unsuitable for our context, so the 
yet to be finalised and approved Oxford/AstraZeneca is likely to be 
the first available to us. And then there is the politics – and hasn’t 
so much of this pandemic been about politics! South Africa has 
apparently missed the first payment of ZAR500 million to secure our 
place on COVAX, a UN-sponsored global vaccine initiative.[6] This is 
the first payment required to ensure that we can secure enough doses 
of whichever vaccine becomes available for 10% of our population of 
56 million to be vaccinated. The Solidarity Fund is now expected to 
step in and make a payment of ZAR300 million, or 15% of the total 
envisaged spend, still requiring a further ZAR4.5 billion. It would 
seem that ZAR10 billion for our failed 
state airline takes greater priority, although 
apparently that too is simply a number 
at the moment! So, my take on getting a 
vaccine in South Africa any time soon? 
I wouldn’t rush to book your next flight to 
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